Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome

Wanner, Vivian; García-Malo, Celia; Romero, Sofía; Cano-Pumarega, Irene; Garcı́a-Borreguero, Diego

doi:10.1016/bs.apha.2019.02.003

Cited by 19 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suffice it to say that the literature supports a well-established efficacy of gabapentinoids for traditional neuropathic pain indications, with numerous systematic reviews and meta-analyses demonstrating significant and superior benefit in these states [7,8]. Gabapentinoids also demonstrate extra-analgesic utility, including anxiolysis [9], amelioration of restless legs syndrome [10], slow-wave sleep enhancement [11], and substance use disorder mitigation [12,13].…”

Section: The Therapeutic Benefits Of Gabapentinoidsmentioning

confidence: 99%

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

2020

View full text Add to dashboard Cite

Introduction: Recent years have seen a dramatic escalation of off-label prescribing for gabapentin and pregabalin (gabapentinoids) owing in part to generic versions of each being released over the past two decades, but also in part as a response to increasing calls for multimodal and non-opioid pain management strategies. In this context, several recent articles have been published alleging widespread misuse, with speculations on the unappreciated addictive potential of the gabapentinoid class of Digital Features To view digital features for this article go to

show abstract

Section: The Therapeutic Benefits Of Gabapentinoidsmentioning

confidence: 99%

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

2020

View full text Add to dashboard Cite

show abstract

“…10,11 Gabapentinoids are increasingly being utilized in its treatment. [12][13][14][15][16][17][18][19][20][21][22][23][24][25] In this study, the number of patients being on pregabalin and gabapentin was found to be very close. This may be associated with the fact that the PMR specialists do not make distinction while choosing gabapentinoids for pain treatment.…”

Section: Discussionmentioning

confidence: 85%

Retrospective Cohort Study of Gabapentinoid Drug Use in Hospitalized Physical Medicine and Rehabilitation Clinic Patients

Külekçioğlu¹,

Akyüz²,

Çetin³

2022

J PMR Sci

View full text Add to dashboard Cite

The aim of this study is to investigate the gabapentinoid utilization rates in musculoskeletal system inpatients and to review the conditions, doses and durations of utilization. Material and Methods: All inpatients over 18 receiving treatment in Physical Medicine and Rehabilitation Clinic of Bursa City Hospital between July 2019 and July 2020 were included in this retrospective study regardless of gender differences. The demographic characteristics of patients, smoking habits, diagnoses, the name of the gabapentinoid drug utilized, the dose used, the duration of utilization, and other drugs utilized concomitantly with gabapentinoid and any additional diseases were recorded. Results: Gabapentinoid use was detected in 173 (27.9%) of 620 patients. It was determined that 88 of 173 patients used gabapentin and 85 were using pregabalin. It was determined that gabapentinoids used mainly for neuropathic pain indication were used at lower doses than recommended. Conclusion: Gabapentinoid use is quite common in our group of inpatients with physical medicine and rehabilitation. More studies are needed to investigate the reasons for using gabapentinoids at lower doses than generally recommended. Although they cause concerns about addiction, their frequent use for pain control shows that gabapentinoids are very beneficial when used in the correct indications and doses.

show abstract

“…The choice of initial treatment for RLS is critical. α2δ Ligands improved symptoms without resulting in augmentation compared to pramipexole in a 1-year study [ 11 ]. Therefore, α2δ ligands may be selected as an initial treatment option, although the common side effects of dizziness, somnolence, fatigue, weight gain, and constipation should be taken into account [ 8 ].…”

Section: Augmentationmentioning

confidence: 99%

“…However, augmentation still occurs to varying degrees with dopaminergic drugs. To address this problem, neurologists have sought to optimize drug usage or seek alternatives such as α2δ ligands [ 11 ] and opioids [ 12 ]. The former—which include gabapentin enacarbil, gabapentin, and pregabalin—have been used for the treatment of RLS since 2000, although they are less frequently prescribed than dopaminergic drugs.…”

Section: Introductionmentioning

confidence: 99%

Pharmacologic Treatment of Restless Legs Syndrome

Wang

Asakawa

et al. 2021

View full text Add to dashboard Cite

: Restless legs syndrome (RLS)/Willis-Ekbom disease is a neurologic disorder characterized by a strong desire to move when at rest (usually in the evening) and paraesthesia in their lower legs. The most widely used therapies for first-line treatment of RLS are dopaminergic drugs; however, their long-term use can lead to augmentation. α2δ Ligands, opioids, iron, glutamatergic drugs, adenosine, and sleep aids have been investigated as alternatives. The pathogenesis of RLS is not well understood. Despite the efficacy of dopaminergic drugs in the treatment of this disorder, unlike in Parkinson’s disease dopaminergic cell loss in the substantia nigra has not been observed in RLS. The etiology of RLS is likely complex, involving multiple neural pathways. RLS-related genes identified in genome-wide association studies can provide insight into the mechanistic basis and pathophysiology of RLS. Here we review the current treatments and knowledge of the mechanisms underlying RLS.

show abstract

Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome

Cited by 19 publications

References 47 publications

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

Retrospective Cohort Study of Gabapentinoid Drug Use in Hospitalized Physical Medicine and Rehabilitation Clinic Patients

Pharmacologic Treatment of Restless Legs Syndrome

Contact Info

Product

Resources

About